Home＞BUSINESS
EA Pharma Licenses Secondary Hyperparathyroidism Med AJT240 to JW Pharma(Nov.2.2017)
EA Pharma, a gastroenterology subsidiary of Eisai, said on October 31 that it has cut a licensing deal with South Korea’s JW Pharmaceutical, granting rights to develop and market its AJT240 for the treatment of secondary hyperparathyroidism in hemodialysis patients in South Korea ...
(LOG IN FOR FULL STORY)
-
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected Apr.20
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers Apr.20
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
